These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 11900526)

  • 1. Molecular crowding accelerates fibrillization of alpha-synuclein: could an increase in the cytoplasmic protein concentration induce Parkinson's disease?
    Shtilerman MD; Ding TT; Lansbury PT
    Biochemistry; 2002 Mar; 41(12):3855-60. PubMed ID: 11900526
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fibrils formed in vitro from alpha-synuclein and two mutant forms linked to Parkinson's disease are typical amyloid.
    Conway KA; Harper JD; Lansbury PT
    Biochemistry; 2000 Mar; 39(10):2552-63. PubMed ID: 10704204
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vesicle permeabilization by protofibrillar alpha-synuclein: implications for the pathogenesis and treatment of Parkinson's disease.
    Volles MJ; Lee SJ; Rochet JC; Shtilerman MD; Ding TT; Kessler JC; Lansbury PT
    Biochemistry; 2001 Jul; 40(26):7812-9. PubMed ID: 11425308
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct.
    Conway KA; Rochet JC; Bieganski RM; Lansbury PT
    Science; 2001 Nov; 294(5545):1346-9. PubMed ID: 11701929
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease.
    Conway KA; Harper JD; Lansbury PT
    Nat Med; 1998 Nov; 4(11):1318-20. PubMed ID: 9809558
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy.
    Conway KA; Lee SJ; Rochet JC; Ding TT; Williamson RE; Lansbury PT
    Proc Natl Acad Sci U S A; 2000 Jan; 97(2):571-6. PubMed ID: 10639120
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Zeroing in on the pathogenic form of alpha-synuclein and its mechanism of neurotoxicity in Parkinson's disease.
    Volles MJ; Lansbury PT
    Biochemistry; 2003 Jul; 42(26):7871-8. PubMed ID: 12834338
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Annular alpha-synuclein protofibrils are produced when spherical protofibrils are incubated in solution or bound to brain-derived membranes.
    Ding TT; Lee SJ; Rochet JC; Lansbury PT
    Biochemistry; 2002 Aug; 41(32):10209-17. PubMed ID: 12162735
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of cytoplasmic alpha-synuclein aggregates. Fibril formation is tightly linked to the inclusion-forming process in cells.
    Lee HJ; Lee SJ
    J Biol Chem; 2002 Dec; 277(50):48976-83. PubMed ID: 12351642
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alpha-synuclein, especially the Parkinson's disease-associated mutants, forms pore-like annular and tubular protofibrils.
    Lashuel HA; Petre BM; Wall J; Simon M; Nowak RJ; Walz T; Lansbury PT
    J Mol Biol; 2002 Oct; 322(5):1089-102. PubMed ID: 12367530
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Beta-synuclein inhibits formation of alpha-synuclein protofibrils: a possible therapeutic strategy against Parkinson's disease.
    Park JY; Lansbury PT
    Biochemistry; 2003 Apr; 42(13):3696-700. PubMed ID: 12667059
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of fibrillization and accumulation of prefibrillar oligomers in mixtures of human and mouse alpha-synuclein.
    Rochet JC; Conway KA; Lansbury PT
    Biochemistry; 2000 Sep; 39(35):10619-26. PubMed ID: 10978144
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Agrin binds alpha-synuclein and modulates alpha-synuclein fibrillation.
    Liu IH; Uversky VN; Munishkina LA; Fink AL; Halfter W; Cole GJ
    Glycobiology; 2005 Dec; 15(12):1320-31. PubMed ID: 16037493
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dependence of alpha-synuclein aggregate morphology on solution conditions.
    Hoyer W; Antony T; Cherny D; Heim G; Jovin TM; Subramaniam V
    J Mol Biol; 2002 Sep; 322(2):383-93. PubMed ID: 12217698
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The association of alpha-synuclein with membranes affects bilayer structure, stability, and fibril formation.
    Zhu M; Li J; Fink AL
    J Biol Chem; 2003 Oct; 278(41):40186-97. PubMed ID: 12885775
    [TBL] [Abstract][Full Text] [Related]  

  • 16. alpha-synuclein fibrillogenesis is nucleation-dependent. Implications for the pathogenesis of Parkinson's disease.
    Wood SJ; Wypych J; Steavenson S; Louis JC; Citron M; Biere AL
    J Biol Chem; 1999 Jul; 274(28):19509-12. PubMed ID: 10391881
    [TBL] [Abstract][Full Text] [Related]  

  • 17. alpha-Synuclein implicated in Parkinson's disease catalyses the formation of hydrogen peroxide in vitro.
    Turnbull S; Tabner BJ; El-Agnaf OM; Moore S; Davies Y; Allsop D
    Free Radic Biol Med; 2001 May; 30(10):1163-70. PubMed ID: 11369507
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interactions among alpha-synuclein, dopamine, and biomembranes: some clues for understanding neurodegeneration in Parkinson's disease.
    Rochet JC; Outeiro TF; Conway KA; Ding TT; Volles MJ; Lashuel HA; Bieganski RM; Lindquist SL; Lansbury PT
    J Mol Neurosci; 2004; 23(1-2):23-34. PubMed ID: 15126689
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Parkinson's disease-associated alpha-synuclein is a calmodulin substrate.
    Martinez J; Moeller I; Erdjument-Bromage H; Tempst P; Lauring B
    J Biol Chem; 2003 May; 278(19):17379-87. PubMed ID: 12610000
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heparin and other glycosaminoglycans stimulate the formation of amyloid fibrils from alpha-synuclein in vitro.
    Cohlberg JA; Li J; Uversky VN; Fink AL
    Biochemistry; 2002 Feb; 41(5):1502-11. PubMed ID: 11814343
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.